| Literature DB >> 33847649 |
Zilin Wan1, Yaxiong Li2, Huishun Ye1, Yunfeng Zi2, Guojing Zhang1, Xiaoyan Wang1.
Abstract
ABSTRACT: To investigate whether plasma concentrations of S100β protein, neuron-specific enolase (NSE), and neuroglobin (NGB) correlate with early postoperative cognitive dysfunction (POCD) in patients undergoing total arch replacement.This prospective study analyzed 40 patients who underwent total arch replacement combined with stented elephant trunk implantation at our hospital between March 2017 and January 2019. Cognitive function was assessed using the Mini-mental State Examination (MMSE) preoperatively, on the day after extubation and on day 7 after surgery. Plasma levels of S100β, NSE, and NGB POCD were assayed preoperatively and at 1, 6, and 24 hours after cardiopulmonary bypass. POCD was defined as a decrease of at least 1 unit in the MMSE score from before surgery until day 7, and patients were stratified into those who experienced POCD or not. The 2 groups were compared in clinicodemographic characteristics and plasma levels of the 3 proteins.Plasma levels of all 3 biomarkers increased significantly during and after cardiopulmonary bypass. Levels of S100β and NSE, but not NGB, were significantly higher in the 15 patients who showed POCD than in the remainder who did not. For prediction of early POCD, S100β showed an area under the receiver operating characteristic curve (AUC) of 0.71 (95% confidence interval [CI] 0.55-0.87), sensitivity of 48%, and specificity of 87%. The corresponding values for NSE were 0.77 (95%CI 0.60-0.94), 92%, and 67%. Together, S100β and NSE showed an AUC of 0.81 (95%CI 0.66-0.96), sensitivity of 73%, and specificity of 80%. NGB did not significantly predict early POCD (AUC 0.62, 95%CI 0.43-0.80).Plasma S100β protein and NSE, but not NGB, may help predict early POCD after total arch replacement.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33847649 PMCID: PMC8051968 DOI: 10.1097/MD.0000000000025446
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Characteristics of patients and surgical procedures.
| Characteristic | Total (n = 40) | POCD (n = 15) | Non-POCD (N = 25) | |
| Demographics | ||||
| Age, yr | 51 ± 11 | 50 ± 10 | 52 ± 12 | .58 |
| Male | 31 (77.5) | 9 (60.0) | 22 (88.0) | .04 |
| Education level | ||||
| Illiterate | 4 (10.00) | 1 (6.67) | 3 (12.00) | .59 |
| Primary school | 14 (35.00) | 5 (33.33) | 9 (36.00) | .86 |
| Middle school or higher | 22 (55.00) | 9 (60.00) | 13 (52.00) | .62 |
| Body mass index, kg/m2 | 25.16 ± 4.60 | 25.79 ± 6.26 | 24.78 ± 3.33 | .51 |
| Current smoker | 7 (17.50) | 1 (6.70) | 6 (24.00) | .16 |
| Current drinker | 4 (10.00) | 2 (13.33) | 2 (8.00) | .59 |
| Hypertension | 34 (85.0) | 14 (93.3) | 20 (80.0) | .25 |
| Ejection fraction | 59.97 ± 6.48 | 61.13 ± 6.06 | 59.28 ± 6.75 | .39 |
| Cardiovascular intervention | 2 (5.00) | 1 (6.67) | 1 (4.00) | .71 |
| Respiratory failure | 27 (67.5) | 9 (60.0) | 18 (72.0) | .43 |
| Atelectasis | 24 (60.0) | 7 (46.7) | 17 (68.0) | .18 |
| Pleural effusion | 25 (62.50) | 9 (60.00) | 16 (64.00) | .80 |
| Renal failure (RIFLE III) | 1 (2.50) | 0 (0.00) | 1 (4.00) | .43 |
| Diabetes | 2 (5.00) | 2 (13.33) | 0 (0.00) | .06 |
| Medications | ||||
| Beta blocker | 10 (25.0) | 3 (20.0) | 7 (28.0) | .57 |
| Anticoagulants | 1 (2.50) | 0 (0.00) | 1 (4.00) | .43 |
| Intraoperative variables | ||||
| Surgery type | ||||
| Aortic valve replacement or valvuloplasty | 5 (12.50) | 2 (13.33) | 3 (12.00) | .90 |
| Coronary artery bypass grafting | 2 (5.00) | 1 (6.67) | 1 (4.00) | .71 |
| Lowest temperature, °C | ||||
| Nasopharyngeal | 24.7 ± 0.8 | 24.7 ± 1.1 | 24.8 ± 0.7 | .71 |
| Rectal | 26.4 ± 1.4 | 25.8 ± 1.4 | 26.8 ± 1.2 | .02 |
| Antegrade cerebral perfusion flow, mL/min/kg | 5.48 ± 0.65 | 5.30 ± 0.31 | 5.59 ± 0.78 | .10 |
| Cardiopulmonary bypass, min | 280 ± 58 | 303 ± 74 | 267 ± 42 | .05 |
| DHCA duration, min | 29 ± 6 | 31 ± 7 | 28 ± 5 | .12 |
| Cross-clamping time, min | 169 ± 42 | 186 ± 51 | 159 ± 32 | .08 |
| Perioperative blood transfusion | ||||
| Red blood cells, units | 6.56 ± 3.28 | 7.27 ± 3.97 | 6.14 ± 2.80 | .30 |
| Fresh frozen plasma, units | 1.79 ± 1.44 | 1.92 ± 1.81 | 1.71 ± 1.20 | .67 |
| Platelet, units | 1.83 ± 0.45 | 1.87 ± 0.52 | 1.80 ± 0.41 | .65 |
Figure 1Flow diagram of patient screening and enrollment.
Scores on the Mini-mental State Examination at different time points.
| Time point | Total (n = 40) | POCD (n = 15) | Non-POCD (n = 25) | |
| Before surgery | 24.90 ± 2.91 | 26.00 ± 2.85 | 24.24 ± 2.79 | .06 |
| After extubation | 23.98 ± 3.42 | 22.73 ± 4.01a | 24.72 ± 2.85 | .08 |
| Day 7 after surgery | 24.23 ± 4.29 | 20.60 ± 5.00a | 26.40 ± 1.50b | <.01 |
| Nadir score after surgery | 21.78 ± 4.17 | 19.40 ± 4.60 | 23.20 ± 3.20 | .01 |
Levels of potential plasma biomarkers of early POCD.
| After surgery | ||||||
| Biomarker | Group | Before surgery | Rewarming to 36°C | 1 h | 6 h | 24 h |
| S100β (ng/mL) | POCD | 0.10 ± 0.04 | 0.16 ± 0.08a | 0.17 ± 0.08b | 0.15 ± 0.08a | 0.12 ± 0.07 |
| Non-POCD | 0.09 ± 0.04 | 0.11 ± 0.06a | 0.12 ± 0.06 | 0.10 ± 0.04 | 0.10 ± 0.05 | |
| .70 | .04 | .03 | .03 | .25 | ||
| NSE (ng/mL) | POCD | 1.26 ± 0.99 | 2.61 ± 1.24b | 2.42 ± 1.11b | 2.02 ± 0.86b | 1.85 ± 1.09a |
| Non-POCD | 0.76 ± 0.69 | 1.56 ± 0.76b | 1.52 ± 0.85b | 1.37 ± 0.78b | 1.21 ± 0.75a | |
| .07 | <.01 | .01 | .02 | .04 | ||
| NGB (ng/mL) | POCD | 9.90 ± 5.78 | 25.41 ± 16.16b | 15.39 ± 7.82a | 14.50 ± 8.22b | 8.47 ± 4.19 |
| Non-POCD | 12.43 ± 6.07 | 20.31 ± 16.61a | 17.97 ± 10.84a | 11.07 ± 6.40 | 10.31 ± 5.70 | |
| .20 | .35 | .43 | .15 | .29 | ||
Figure 2Peak levels of S100β, neuron-specific enolase (NSE), and neuroglobin (NGB) in patients with or without early postoperative cognitive dysfunction (POCD).
Figure 3Receiver operating characteristic curves of (A) each potential biomarker on its own or (B) the combination of S100β and neuron-specific enolase (NSE) for predicting early postoperative cognitive dysfunction.